TC BioPharm - Company Presentation
559 بار بازدید -
10 سال پیش
-
Presented by: Michael Leek, Ph.D.,
Presented by: Michael Leek, Ph.D., CEO
Commercializing the anti-cancer cytotoxicity exhibited by γδ T cells, TC BioPharm is developing an autologous therapy which involves expansion of the cells over a two-three week period to formulate a treatment for a wide-variety of different tumor types. The manufacturing process comprises several steps. The first involves isolation of peripheral blood mononuclear cells; the second involves selection/activation of γδ T cells; the final stage requires culture expansion in a GMP environment, providing therapeutically relevant cell numbers prior to administration. Although there are many different approaches to T cell immunotherapy, the process has a compelling clinical safety and efficacy record, demonstrated by a cohort of published case histories. Moreover, when contrasted with novel immunotherapies such as PDL-1 and CTLA-4 inhibitors being developed by Roche and Bristol Myers Squibb respectively, use of γδ T cells may have a complimentary and synergistic therapeutic benefit.
For more information on the 2014 Stem Cell Meeting on the Mesa visit www.stemcellmeetingonthemesa.com
Commercializing the anti-cancer cytotoxicity exhibited by γδ T cells, TC BioPharm is developing an autologous therapy which involves expansion of the cells over a two-three week period to formulate a treatment for a wide-variety of different tumor types. The manufacturing process comprises several steps. The first involves isolation of peripheral blood mononuclear cells; the second involves selection/activation of γδ T cells; the final stage requires culture expansion in a GMP environment, providing therapeutically relevant cell numbers prior to administration. Although there are many different approaches to T cell immunotherapy, the process has a compelling clinical safety and efficacy record, demonstrated by a cohort of published case histories. Moreover, when contrasted with novel immunotherapies such as PDL-1 and CTLA-4 inhibitors being developed by Roche and Bristol Myers Squibb respectively, use of γδ T cells may have a complimentary and synergistic therapeutic benefit.
For more information on the 2014 Stem Cell Meeting on the Mesa visit www.stemcellmeetingonthemesa.com
10 سال پیش
در تاریخ 1393/07/30 منتشر شده
است.
559
بـار بازدید شده